These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

397 related items for PubMed ID: 17630551

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program.
    Braitstein P, Zala C, Yip B, Brinkhof MW, Moore D, Hogg RS, Montaner JS.
    J Infect Dis; 2006 Jan 15; 193(2):259-68. PubMed ID: 16362890
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.
    Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, Kirk O, Phillips A, Ledergerber B, Lundgren J, EuroSIDA Study Group.
    J Infect Dis; 2005 Sep 15; 192(6):992-1002. PubMed ID: 16107951
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Performance of a World Health Organization first-line regimen (stavudine/lamivudine/nevirapine) in antiretroviral-naïve individuals in a Western setting.
    Tam LW, Hogg RS, Yip B, Montaner JS, Harrigan PR, Brumme CJ.
    HIV Med; 2007 Jul 15; 8(5):267-70. PubMed ID: 17561871
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study.
    Manosuthi W, Chumpathat N, Chaovavanich A, Sungkanuparph S.
    BMC Infect Dis; 2005 Aug 24; 5():67. PubMed ID: 16120209
    [Abstract] [Full Text] [Related]

  • 14. Weight and body shape changes in a treatment-naive population after 6 months of nevirapine-based generic highly active antiretroviral therapy in South India.
    Saghayam S, Kumarasamy N, Cecelia AJ, Solomon S, Mayer K, Wanke C.
    Clin Infect Dis; 2007 Jan 15; 44(2):295-300. PubMed ID: 17173234
    [Abstract] [Full Text] [Related]

  • 15. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy.
    Lima VD, Hogg RS, Harrigan PR, Moore D, Yip B, Wood E, Montaner JS.
    AIDS; 2007 Mar 30; 21(6):685-92. PubMed ID: 17413689
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.
    Bani-Sadr F, Lapidus N, Bedossa P, De Boever CM, Perronne C, Halfon P, Pol S, Carrat F, Cacoub P, French National Agency for Research on AIDS, Viral Hepatitis-HC02-Ribavic Study Team.
    Clin Infect Dis; 2008 Mar 01; 46(5):768-74. PubMed ID: 18248298
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.